-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Unicycive Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2023.
- Unicycive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was $9.86M.
- Unicycive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$23.2M, a 20.7% increase year-over-year.
- Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$30.5M, a 69.1% decline from 2022.
- Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.1M, a 80.3% decline from 2021.
- Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$10M, a 342% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)